These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Therapeutic advances in metastatic pancreatic adenocarcinoma and related cancers: focus on evidence-based and sequenced approaches to survival extension in metastatic pancreatic adenocarcinoma. Bekaii-Saab T; Yu K; Lima CMSR; Wolin EM Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):1-16. PubMed ID: 30807558 [No Abstract] [Full Text] [Related]
5. Treatment of advanced pancreatic cancer. Labianca R; Merelli B; Mosconi S Ann Oncol; 2012 Sep; 23 Suppl 10():x139-40. PubMed ID: 22987950 [No Abstract] [Full Text] [Related]
6. A review of systemic therapy for advanced pancreatic cancer. El-Rayes BF; Philip PA Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429 [TBL] [Abstract][Full Text] [Related]
7. Current status of chemotherapy in metastatic pancreatic cancer. Wils JA Anticancer Res; 1989; 9(4):1027-31. PubMed ID: 2683988 [TBL] [Abstract][Full Text] [Related]
8. Metastatic pancreatic adenocarcinoma: current standards, future directions. Duffy A; Kummar S Am J Ther; 2010; 17(1):79-85. PubMed ID: 19636248 [TBL] [Abstract][Full Text] [Related]
9. Phase 1 trials in pancreatic cancer. Yu E; Saif MW; Huber K JOP; 2014 Jul; 15(4):326-8. PubMed ID: 25076334 [TBL] [Abstract][Full Text] [Related]
11. Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma. Lima CMSR Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):3-5. PubMed ID: 30807559 [No Abstract] [Full Text] [Related]
14. A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma. Bekaii-Saab T Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):5-7. PubMed ID: 30807560 [No Abstract] [Full Text] [Related]
15. New guideline-sanctioned and emerging interventions for pancreatic cancer. Bekaii-Saab T Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):7-9. PubMed ID: 30807561 [No Abstract] [Full Text] [Related]
16. Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen. Yoo C; Kim BJ; Kim KP; Lee JL; Kim TW; Ryoo BY; Chang HM Cancer Res Treat; 2017 Jul; 49(3):759-765. PubMed ID: 27857025 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer. Sullivan KM; Kozuch PS Cancer J; 2012; 18(6):633-41. PubMed ID: 23187852 [TBL] [Abstract][Full Text] [Related]
18. Gemcitabine in the treatment of metastatic pancreatic cancer. Hilbig A; Oettle H Expert Rev Anticancer Ther; 2008 Apr; 8(4):511-23. PubMed ID: 18402518 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Rubinson DA; Wolpin BM Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909 [TBL] [Abstract][Full Text] [Related]